Global Blood Plasma Market Report: 2013 Edition- New Report by Koncept Analytics

March 12, 2013 - PRLog -- Plasma is the liquid component of blood, constituting around 50% of the total blood volume. Plasma in itself is approximately 90% water, with the remaining 10% comprising of proteins, minerals, clotting factors, hormones, and immunoglobins. Plasma is the raw material for the extraction of various proteins which are used for their therapeutic values. Plasma proteins cannot be manufactured rather the same are obtained or collected from a large pool of donors.

With the swift progression in the field of biomedical/healthcare technology, companies operating in the healthcare/pharmaceutical/therapeutic industry are now surmounting in the respective realm. In order to address the unmet medical needs related to blood disorders, autoimmune diseases and liver function impairment among others, associated companies are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma.

The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. The rivalry prevalent in the global blood plasma market is quite fierce with numerous local and global players contenting for the market share. On the global front, the key players are Baxter, CSL, Grifols and Octapharma.

This report consists of the following sections:

1. Overview
1.1 Components of Blood Plasma
1.2 Functions of Blood Plasma
1.3 Collection and Extraction of Plasma
1.3.1 Plasma Collection
1.3.2 Plasma Extraction
1.3.3 Plasma Fractionation Yield
1.3.4 Plasma Usage

2. Blood Plasma Market Structure

2.1 Global Blood Plasma Market
2.1.1 Plasma Industry Cost Structure
2.1.2 Plasma Market of the US

2.2 Global IVIG Market
2.2.1 IVIG Market of the US

2.3 Global Hemophilia Market
2.3.1 FVIII Market of the US

2.4 Albumin Market
2.4.1 Albumin Market of China and the US

3. Market Dynamics

3.1 Key Trends
3.1.1 Kinetics of Plasma-collection Industry
3.1.2 Reimbursement
3.1.3 Growing Penetration of rFVIII Products in Emerging Markets – Opportunity for Manufacturers
3.1.4 A1PI Deficiency- Confined to Prevention only

3.2 Industry Developments
3.2.1 Improved Biological Molecule Formulations
3.2.2 Baxter’s Phase I Clinical Trial of Treatment for Hemophilia A

3.3 Growth Drivers
3.3.1 Increasing New Patient Registration for Hemophilia Treatment
3.3.2 Increased Usage of Plasma Derived Products
3.3.3 Rising Healthcare Expenditure
3.3.4 Higher Spending on Medicines
3.3.5 Rising Demand for Better Healthcare Options
3.3.6 Launch of NMEs (New Molecular Entities)
3.3.7 Growing Ageing Population (+60 Years)
3.3.8 Rising Male Population
3.3.9 Ameliorating Economic Conditions

3.4 Challenges
3.4.1 Increasing regulation in the plasma-collection industry
3.4.2 Escalating Price Pressure
3.4.3 Constrained Plasma Fractionation Capacity
3.4.4 Misdiagnosis of the Disease

4. Competitive Landscape
4.1 Blood Plasma Market Rivalry
4.2 Plasma Derivatives Market Contention
4.2.1 Immunoglobulins
-IVIG Market of Europe
-IVIG Market of North America
-IVIG Market of the US
4.2.2 Albumin Market
-Albumin Market of the US
-Albumin Market of China
4.2.3 Other Products

5. Company Profiles
5.1 Baxter International Inc.
5.2 Grifols
5.3 CSL Limited
5.4 Octapharma

6. Market Outlook
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis

List of Charts

Plasma Extraction from Donated Blood (Recovered Plasma)
Plasmapheresis (Source Plasma)
Global Blood Plasma Market (2000-2011)
Global Plasma Market Share by Product (2011)
Manufacturing Cost Split for Plasma Fractionation (September 2011)
Plasma Derivative Sales in the US (2005-2011)
US Source Plasma Collections (2007-2012E)
Global IVIG Market Size (2004-2011)
Global IVIG Demand and Supply (2007-2012E)
IVIG Market Volume by Region (2005, 2008 and 2011)
Global IVIG Market Share by Geography (2011)
IVIG Use by Indication
Sales of IVIG in the US (2001-2011)
Global Hemophilia Treatment Market Revenues (2006-2012)
Global FVIII Market (2011)
Global FIX Market (2011)
Annual Global Sales of NovoSeven (2007-2011)
Monthly Distribution of FVIII in the US (January 2011-September 2012)
Albumin Market Size of the US and China
Albumin Price across US and China
China’s Plasma Protein Market Growth (October 2012)
Monthly Distribution of Albumin 25% in the US (January 2011-Sptember 2012)
Monthly Distribution of Albumin 25% in the US (January 2011-Sptember 2012)
Licensed Plasma Centers in the US and their profitability (FY06-FY11)
A1PI Statistics of North America and EU
Per Capita Usage of FVIII in Developed Countries
Per Capita Usage of FVIII in Developing Countries
Per Capita FIX Usage in Developed Economies
Per Capita FIX Usage in Emerging Economies
Global Healthcare Spending (2005-2015E)
Global Spending on Medicines (2006-2016E)
Global Spending on Medicine Share by Region (2006-2016E)
The US Spending on Medicine (2007-2016E)
Japan’s Spending on Medicine (2007-2016E)
Biotechnology Therapeutics Under Development (2011)
Global Ageing Population (2005-2013F)
Global Male Population (2005-2014F)
Global GDP (2001-2011)
World GDP per Capita (2005-2011)
Global Plasma Market Share by Company (2011)
Aligned PCCs vs. independent PCCs Share in the US (2011)
Europe’s IVIG Market Share (2011)
North America’s IVIG Market Share (2011)
US IVIG Market (2011)
US Albumin Market Share (2011)
China’s Albumin Market (2011-12)
Product Rivalry in the US (2011)
Baxter’s Revenue by Business Segments (2011)
Baxter’s Revenues and Net Income (2008-2011)
Grifols Revenue Share by Business Segments (2011)
Grifols’ Revenues & Profits (2008-2011)
CSL’s Revenue Share by Major Products (2011-12)
CSL’s Revenues and Net Profit (2008/09-2011/12)
Octapharma’s Net Sales and Net Profit (2008-2011)
Global Blood Plasma Market Forecast (2009-2015F)

List of Tables

Constituents of Blood Plasma
Recovered plasma vs. Source plasma
Output per Liter of Plasma
Breakdown of US IVIG usage by Patient Share & Volume Share by Indication
Breakdown of US SCIG and IVIG Usage by Volume Share (FY11)
US Centre for Medicare and Medicaid (CMS) Reimbursement
Conversion to Recombinant Factor VIII Products in Selected Countries (2010)
A1PI Products
Long Acting FIX & FVIII under Late-Stage Development
Extended Half Life rFVIII Agents
Extended Half Life rFIX Agents
New Patient Registrations in Worldwide Bleeding Disorders Market (2008-2013E)
Patients Worldwide Waiting for Better Treatment Options (2011)
Global Availability of NMEs (2011)
IVIG Product Characteristics
Dependent & Independent Variables (2007-2011)
Correlation Matrix
Regression Coefficients Output

For further details, kindly visit: http://www.konceptanalytics.com/reportDetail.aspx?reportI...